ArticleVascular health and risk management2025
Selenium and Lead Exposure are Associated with Elevated Blood Pressure in Individuals with Undiagnosed Hypertension: Findings from NHANES 2013-2020.
Article in Vascular health and risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Prior studies on the relationship between metal exposure and blood pressure have reported inconsistent findings, potentially due to the inclusion of individuals receiving hypertension treatment. This study assessed the association between blood concentrations of selenium (Se), lead (Pb), total mercury (Hg), cadmium (Cd), and manganese (Mn) and elevated blood pressure in US adults aged 20-60 years without a prior hypertension diagnosis. We also explored the moderating effects of age, gender and body mass index (BMI), and the mediating role of non-high-density lipoprotein cholesterol (non-HDL-C). Methods: Data from the 2013-2020 National Health and Nutrition Examination Survey were analyzed. Weighted logistic regression model were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), with subgroup analyses assessing effect modification. Structural equation modelling was employed to evaluated the potential mediating effects of non-HDL-C. Results: Among 6026 participants, 1,569 had elevated blood pressure. Adjusted analyses showed significant associations between Se and Pb and increased hypertension odds. Each 1 μg/L increase in Se corresponded to a 1% rise in odds (OR: 1.01, 95% CI: 1.00, 1.01), with those in the highest Se quintiles (Q4 and Q5) having 49% (95% CI: 1.01-2.21) and 52% (95% CI: 1.01-2.27) greater odds, respectively. A unit increase in log-transformed Pb was associated with a 36% increase in odds (95% CI: 1.09-1.71), with the highest Pb quintile showing nearly double the risk (OR: 1.94; 95% CI: 1.22-3.07). BMI significantly moderated the association with Se and Pb, albeit in different ways. Non-HDL-C mediated 36.82% of Se's and 30.80% of Pb's total effect on elevated blood pressure (p<0.05). Conclusion: In US adults without diagnosed hypertension, higher blood Se and Pb concentrations were associated with elevated blood pressure, with BMI modifying and non-HDL-C potentially and partially mediating these associations. These findings highlight the need for targeted public health strategies to limit environmental metal exposure and suggest that monitoring non-HDL-C levels in conjunction with individual metabolic profiles may support early cardiovascular risk assessment and timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.